PT - JOURNAL ARTICLE AU - Eric Lai AU - David Becker AU - Pius Brzoska AU - Tyler Cassens AU - Jeremy Davis-Turak AU - Evan Diamond AU - Manohar Furtado AU - Manoj Gandhi AU - Dale Gort AU - Alexander L. Greninger AU - Pooneh Hajian AU - Kathleen Hayashibara AU - Emily B. Kennedy AU - Marc Laurent AU - William Lee AU - Nicole A. Leonetti AU - Jean Lozach AU - James Lu AU - Jason M. Nguyen AU - K. M. Clair O’Donovan AU - Troy Peck AU - Gail E. Radcliffe AU - Jimmy M. Ramirez AU - Pavitra Roychoudhury AU - Efren Sandoval AU - Brian Walsh AU - Marianne Weinell AU - Cassandra Wesselman AU - Timothy Wesselman AU - Simon White AU - Stephen Williams AU - David Wong AU - Yufei Yu AU - Richard S. Creager TI - A method for variant agnostic detection of SARS-CoV-2, rapid monitoring of circulating variants, detection of mutations of biological significance, and early detection of emergent variants such as Omicron AID - 10.1101/2022.01.08.22268865 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.08.22268865 4099 - http://medrxiv.org/content/early/2022/01/09/2022.01.08.22268865.short 4100 - http://medrxiv.org/content/early/2022/01/09/2022.01.08.22268865.full AB - The rapid emergence of new SARS-CoV-2 variants raises a number of public health questions including the capability of diagnostic tests to detect new strains, the efficacy of vaccines, and how to map the geographical distribution of variants to better understand patterns of transmission and possible load on healthcare resources. Next-Generation Sequencing (NGS) is the primary method for detecting and tracing the emergence of new variants, but it is expensive, and it can take weeks before sequence data is available in public repositories. Here, we describe a Polymerase Chain Reaction (PCR)-based genotyping approach that is significantly less expensive, accelerates reporting on SARS-CoV-2 variants, and can be implemented in any testing lab performing PCR.Specific Single Nucleotide Polymorphisms (SNPs) and indels are identified that have high positive percent agreement (PPA) and negative percent agreement (NPA) compared to NGS for the major genotypes that circulated in 2021. Using a 48-marker panel, testing on 1,128 retrospective samples yielded a PPA and NPA in the 96.3 to 100% and 99.2 to 100% range, respectively, for the top 10 most prevalent lineages. The effect on PPA and NPA of reducing the number of panel markers was also explored.In addition, with the emergence of Omicron, we also developed an Omicron genotyping panel that distinguishes the Delta and Omicron variants using four (4) highly specific SNPs. Data from testing demonstrates the capability to use the panel to rapidly track the growing prevalence of the Omicron variant in the United States in December 2021.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch reported in this publication was supported by the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health (under award numbers 75N92019P00328, U54EB015408, and U54EB027690) as part of the Rapid Acceleration of Diagnostics (RADx) initiative, launched to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing. The funders had no role in the decision to submit the work for publication and the views expressed herein are the authors' and do not necessarily represent the views of the National Institutes of Health or the United States Department of Health and Human Services.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Helix OpCo samples: Western Institutional Review Board-Copernicus Group (WCG), the Institutional Review Board (IRB) of record for the Helix Respiratory Registry, gave ethical approval for this work. University of Washington Samples: The IRB of the University of Washington (UW) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://tracker.rosalind.bio https://www.gisaid.org/